Venturi C, Bueno J, Gavalda J, Tórtola T, Pou L, Medina A, Codina G, Charco R, Pahissa A
Unidad de Trasplante Hepático Infantil, Hospital Universitario Valle de Hebron, Barcelona, Spain.
Transplant Proc. 2009 Apr;41(3):1038-40. doi: 10.1016/j.transproceed.2009.02.053.
Preemptive therapy with ganciclovir has been recommended in the pediatric liver transplant strategy to avoid the development of posttransplant lymphoproliferative disorder (PTLD) from an high Epstein-Barr virus (EBV) is detected. We sought viral load to analyze the response to preemptive therapy with valganciclovir (VGC) in children with liver transplantations and an high quantitative EBV-PCR.
From June 2005 to December 2007, we tested 979 EBV-PCR among 80 pediatric liver transplant recipients, from those 21/80 PCR were tested from the date of transplantation and 59/80 belonged to the historical cohort (7/59 had a prior history of PTLD). Patients were divided into 2 groups depending upon whether they did (n = 22) or did not (n = 19) receive VGC treatment. The response to VGC was considered complete, if the PCR was negative at 30 and 60 days of treatment; and partial, when the PCR decreased at least 50%. Ganciclovir blood levels tested in 109 cases instances and correlated with the EBV-PCR.
A total of 369 (33%) positive PCR were detected in 36/80 patients (mean, 75,000 copies; range = 5000-4,200,000). Among the 22 episodes treated for 30 days, 34% showed complete responses, 41%, partial, and 23%, no response. Among the non-treated group the rates were 6%, 25%, and 68%, respectively (P = .01). However, no differences were observed among those episodes treated for 60 days. At the administered doses, hardly any patient reached the recommended ganciclovir therapeutic level at 2 hours (6 micro/mL). However, the mean PCR was lower when the ganciclovir levels were greater than 4 mg/L when compared with lower levels (P = .03).
After 30 days of treatment there was a response to VGC in the EBV viral load. There was high interpatient variability of ganciclovir serum concentrations, suggesting the need for pharmacokinetic monitoring to optimize treatment. There was a relationship between the concentration of ganciclovir and the EBV viral load.
在小儿肝移植策略中,已推荐使用更昔洛韦进行抢先治疗,以避免在检测到高 Epstein-Barr 病毒(EBV)时发生移植后淋巴细胞增生性疾病(PTLD)。我们寻求病毒载量以分析肝移植儿童中使用缬更昔洛韦(VGC)进行抢先治疗的反应以及高定量 EBV-PCR 情况。
2005 年 6 月至 2007 年 12 月,我们在 80 名小儿肝移植受者中检测了 979 次 EBV-PCR,其中 21/80 的 PCR 检测是从移植日期开始的,59/80 属于历史队列(59 例中有 7 例有 PTLD 病史)。根据患者是否接受 VGC 治疗分为两组(n = 22)或未接受(n = 19)。如果治疗 30 天和 60 天时 PCR 为阴性,则认为对 VGC 的反应为完全反应;当 PCR 至少降低 50%时,则为部分反应。在 109 例病例中检测了更昔洛韦血药浓度,并与 EBV-PCR 相关。
在 36/80 例患者中总共检测到 369 次(33%)阳性 PCR(平均 75,000 拷贝;范围 = 5000 - 4,200,000)。在接受 30 天治疗的 22 例中,34%显示完全反应,41%为部分反应, 23%无反应。在未治疗组中,比例分别为 6%、25%和 68%(P = .01)。然而,在接受 60 天治疗的病例中未观察到差异。在给药剂量下,几乎没有患者在 2 小时时达到推荐的更昔洛韦治疗水平(6 μg/mL)。然而,与较低水平相比,当更昔洛韦水平大于 4 mg/L 时,平均 PCR 较低(P = .03)。
治疗 30 天后,EBV 病毒载量对 VGC 有反应。更昔洛韦血清浓度在患者间存在高度变异性,表明需要进行药代动力学监测以优化治疗。更昔洛韦浓度与 EBV 病毒载量之间存在关联。